The Case for Prescribing Metformin Off-Label for a Child in Remission from Ependymoma

Pediatrics often faces ethical challenges when families request unproven therapies. We respond to a clinical case described in “A Parental Request for an Unproven Treatment for a Rare Pediatric Cancer: Sound Reasons for Not Going Off-Label,” by Margot Hedlin and Louis Voigt, in the same issue of thi...

Ausführliche Beschreibung

Gespeichert in:  
Bibliographische Detailangaben
VerfasserInnen: Hahn, Emily S. (Verfasst von) ; Hedlin, Margot (Verfasst von)
Medienart: Elektronisch Aufsatz
Sprache:Englisch
Verfügbarkeit prüfen: HBZ Gateway
Fernleihe:Fernleihe für die Fachinformationsdienste
Veröffentlicht: 2026
In: The Hastings Center report
Jahr: 2026, Band: 56, Heft: 2, Seiten: 16-18
weitere Schlagwörter:B pediatric ethics
B pediatric oncology
B family-centered care
B clinical ethics
B off-label prescribing
Online-Zugang: Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000naa a22000002c 4500
001 1965621287
003 DE-627
005 20260318055505.0
007 cr uuu---uuuuu
008 260318s2026 xx |||||o 00| ||eng c
024 7 |a 10.1002/hast.70044  |2 doi 
035 |a (DE-627)1965621287 
035 |a (DE-599)KXP1965621287 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Hahn, Emily S.  |e VerfasserIn  |4 aut 
245 1 4 |a The Case for Prescribing Metformin Off-Label for a Child in Remission from Ependymoma 
264 1 |c 2026 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a Pediatrics often faces ethical challenges when families request unproven therapies. We respond to a clinical case described in “A Parental Request for an Unproven Treatment for a Rare Pediatric Cancer: Sound Reasons for Not Going Off-Label,” by Margot Hedlin and Louis Voigt, in the same issue of this journal. The case concerns Natalie, a three-year-old in remission from ependymoma, whose parents requested metformin to prevent recurrence. Although Natalie's neuro-oncologist opposed the use of the drug, its favorable safety profile, pediatric Food and Drug Administration approval for other indications, emerging evidence in cancer research, and endorsement by a specialist support careful consideration. Off-label prescribing is common in pediatric oncology due to issues presented by rare diseases and due to the limitations of clinical trials. With informed consent, monitoring, and interdisciplinary input about the patient's care, prescribing metformin may be ethically justifiable despite uncertain efficacy. This case illustrates the balance between evidence-based practice, patient- and family-centered care, and the realities of pediatric cancer treatment. 
650 4 |a pediatric ethics 
650 4 |a family-centered care 
650 4 |a off-label prescribing 
650 4 |a clinical ethics 
650 4 |a pediatric oncology 
700 1 |a Hedlin, Margot  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |a Hastings Center  |t The Hastings Center report  |d Malden, Mass. : Wiley, 1971  |g 56(2026), 2, Seite 16-18  |h Online-Ressource  |w (DE-627)341346551  |w (DE-600)2067369-3  |w (DE-576)258761822  |x 1552-146X  |7 nnas 
773 1 8 |g volume:56  |g year:2026  |g number:2  |g pages:16-18 
856 4 0 |u https://doi.org/10.1002/hast.70044  |x Resolving-System  |z lizenzpflichtig  |3 Volltext  |7 1 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/hast.70044  |x Verlag  |z lizenzpflichtig  |3 Volltext  |7 1 
912 |a NOMM 
935 |a mteo 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4937740903 
LOK |0 003 DE-627 
LOK |0 004 1965621287 
LOK |0 005 20260318055505 
LOK |0 008 260318||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2026-03-17#7AA0A1F9012D815B5BD7CDBBDABA94E71E152485 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 935   |a ixzs  |a zota  |a tiep 
LOK |0 939   |a 2026-03-18  |b l01 
ORI |a TA-MARC-ixtheoa001.raw